4 results on '"Sanchez-Pastor L"'
Number of results to display per page
Search Results
2. Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis
- Author
-
González-Blanco, Leticia, García-Portilla, María Paz, Gutiérrez, Miguel, Mezquida, Gisela, Cuesta, Manuel J., Urbiola, Elena, Amoretti, Silvia, Barcones, Fe, González-Pinto, Ana, Pina-Camacho, Laura, Corripio, Iluminada, Vieta, Eduard, Baeza, Inmaculada, Toll, Alba, Sáiz, Pilar A., Bobes, Julio, Bernardo, Miguel, Bioque, Miquel, Sagué, M., Alonso-Solís, Anna, Grasa, Eva, González-Ortega, I., Zorrilla, I., Santabárbara, J., De-la-Cámara, C., Aguilar, E.J., Nacher, J., Bergé Baquero, Daniel, Mané, Anna, Montejo, L., Anmella, Gerard, Castro-Fornieles, Josefina, de la Serna, Elena, Contreras, F., Sáiz-Masvidal, C., García-Álvarez, L., Bobes-Bascarán, T., Zabala-Rabadán, A., Segarra-Echevarría, R., Sanchez-Pastor, L., Rodriguez-Jimenez, R., Usall, J., Butjosa, A., Sarró, S., Guerrero-Pedraza, A., Ibáñez, Ángela, Ribeiro, M., Balanzá-Martínez, Vicent, and Universitat Autònoma de Barcelona
- Subjects
medicine.medical_specialty ,Tobacco use ,Prodromal symptoms ,European Regional Development Fund ,First psychotic symptoms ,Substance use ,Tobacco Use ,Political science ,First episode psychosis ,Health care ,medicine ,Humans ,media_common.cataloged_instance ,In patient ,European union ,Psychiatry ,Biological Psychiatry ,Cannabis ,Retrospective Studies ,media_common ,biology ,business.industry ,biology.organism_classification ,Psychiatry and Mental health ,Psychotic Disorders ,Schizophrenia ,Christian ministry ,business - Abstract
OBJECTIVE: There is high prevalence of cigarette smoking in individuals with first-episode psychosis (FEP) prior to psychosis onset. The purpose of the study was to determine the impact of previous tobacco use with or without cannabis on first psychotic experiences in FEP and the impact of this use on age of onset of symptoms, including prodromes. METHODS: Retrospective analyses from the naturalistic, longitudinal, multicentre, "Phenotype-Genotype and Environmental Interaction. Application of a Predictive Model in First Psychotic Episodes (PEPs)" Study. The authors analysed sociodemographic/clinical data of 284 FEP patients and 231 matched healthy controls, and evaluated first psychotic experiences of patients using the Symptom Onset in Schizophrenia Inventory. RESULTS: FEP patients had significantly higher prevalence of tobacco, cannabis, and cocaine use than controls. The FEP group with tobacco use only prior to onset (N=56) had more sleep disturbances (42.9% vs 18.8%, P=0.003) and lower prevalence of negative symptoms, specifically social withdrawal (33.9% vs 58%, P=0.007) than FEP with no substance use (N=70), as well as lower prevalence of ideas of reference (80.4% vs 92.4%, P=0.015), perceptual abnormalities (46.4% vs 67.4%, P=0.006), hallucinations (55.4% vs 71.5%, P=0.029), and disorganised thinking (41.1% vs 61.1%, P=0.010) than FEP group with previous tobacco and cannabis use (N=144). FEP patients with cannabis and tobacco use had lower age at first prodromal or psychotic symptom (mean=23.73years [SD=5.09]) versus those with tobacco use only (mean=26.21 [SD=4.80]) (P=0.011). CONCLUSIONS: The use of tobacco alone was not related to earlier age of onset of a first psychotic experience, but the clinical profile of FEP patients is different depending on previous tobacco use with or without cannabis. This study received economic support from the Spanish Ministry of Economic Affairs and Competitiveness, the Carlos III Health Care Insti-tute (Grant Number PI11/00325, PI14/00612), the European Regional Development Fund, the European Union, “Una manera de hacer Europa/ A Way of Shaping Europe”, and CIBERSAM.
- Published
- 2021
3. P.6.a.006 Clinical variables related to attentional bias associated with alcohol cues
- Author
-
Trujillo, F., Marín, M., Chamorro, J., Curibil, P., Sánchez-Pastor, L., Martínez-Gras, I., Ponce, G., and Rubio, G.
- Published
- 2010
- Full Text
- View/download PDF
4. The polygenic basis of relapse after a first episode of schizophrenia.
- Author
-
Segura ÀG, Prohens L, Gassó P, Rodríguez N, Garcia-Rizo C, Moreno-Izco L, Andreu-Bernabeu Á, Zorrilla I, Mane A, Rodriguez-Jimenez R, Roldán A, Sarró S, Ibáñez Á, Usall J, Sáiz PA, Cuesta MJ, Parellada M, González-Pinto A, Berrocoso E, Bernardo M, Mas S, Mezquida G, Arbelo N, De Matteis M, Galvañ J, Duque Guerra A, Arias I Queralt L, Perez-Bacigalupe M, Gonzalez-Ortega I, Toll A, Casanovas F, Sanchez-Pastor L, Valtueña M, Pomarol-Clotet E, García-León MÁ, Butjosa A, Rubio-Abadal E, Ribeiro M, López-Ilundain JM, Saiz-Ruiz J, León-Quismondo L, Rivero O, Ruiz P, Echevarría RS, and García-Portilla MP
- Abstract
Little is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were included (56 patients who had not experienced relapse after 3 years of enrollment and 58 patients who relapsed during the 3-year follow-up). PRS for schizophrenia (PRS-SZ), bipolar disorder (PRS-BD), education attainment (PRS-EA) and cognitive performance (PRS-CP) were used to assess the genetic risk of schizophrenia relapse.Patients with higher PRS-EA, showed both a lower risk (OR=0.29, 95% CI [0.11-0.73]) and a later onset of relapse (30.96± 1.74 vs. 23.12± 1.14 months, p=0.007. Our study provides evidence that the genetic burden of neurocognitive function is a potentially predictors of relapse that could be incorporated into future risk prediction models. Moreover, appropriate treatments for cognitive symptoms appear to be important for improving the long-term clinical outcome of relapse., Competing Interests: Conflict of interest A. Ibáñez has received research support from or served as speaker or advisor for Janssen-Cilag, Lundbeck and Otsuka. A. Gonzalez-Pinto has received grants and served as consultant, advisor or CME speaker for the following entities: Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Sanofi-Aventis, Exeltis, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), and the Basque Government, J. Saiz-Ruiz has been as speaker for and on the advisory boards of Adamed, Lundbeck, Servier, Medtronic, Casen Recordati, Neurofarmagen, Otsuka, Indivior, Lilly, Schwabe, Janssen and Pfizer, outside the submitted work. M. Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Angelini, Casen Recordati, Janssen-Cilag, Menarini, Rovi and Takeda, Pilar A. Saiz has been a consultant to and/or has received honoraria or grants from Adamed, CIBERSAM, European Comission, Government of the Principality of Asturias, Instituto de Salud Carlos III, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Plan Nacional Sobre Drogas and Servier. R. Rodriguez-Jimenez has been a consultant for, spoken in activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES; S2017/BMD-3740), JanssenCilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste, Takeda, Exeltis, Casen-Recordati, Angelini. The rest of the authors reported no biomedical financial interests or potential conflicts of interest., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.